Pelabresib,Ruxolitinib
morphosys
['$mor', 'morphosys']
$mor morphosys presents multiple analyses of the manifest phase 2 trial investigating the potential of pelabresib in the treatment of myelofibrosis at eha 2022 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities